Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANN M REED

Allopathic & Osteopathic Physicians Dermatology

NPI
1669717773
CMS profile
166865
Location
BOCA RATON, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$28,288.05

160 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 4 of 4; records 151–160 of 160 matching records. This page contains 10 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANN M REED

NPI 1669717773 · CMS profile ID 166865

Allopathic & Osteopathic Physicians / Dermatology

BOCA RATON, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–160 of 160 matching records. This page contains 10 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1669717773?year=2025&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANN M REED, NPI 1669717773, CMS profile ID 166865. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–160 of 160 matching records. This page contains 10 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1669717773?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). ANN M REED, NPI 1669717773, CMS profile ID 166865. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–160 of 160 matching records. This page contains 10 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1669717773?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
ANN M REED, NPI 1669717773, CMS profile ID 166865, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–160 of 160 matching records. This page contains 10 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1669717773?year=2025&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

160 matching records · $28,288.05 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 160 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–160 of 160.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $18.9301/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203809950 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $20.6701/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250970398 CMS
ABBVIE INC. $25.1601/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203809939 CMS
Arcutis Biotherapeutics, Inc. $4.4201/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252328468 CMS
ABBVIE INC. $9.9001/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203809933 CMS
GENZYME CORPORATION $30.0701/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233520415 CMS
Arcutis Biotherapeutics, Inc. $3.8801/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252328462 CMS
Arcutis Biotherapeutics, Inc. $3.0401/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252328464 CMS
ABBVIE INC. $23.3001/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203809928 CMS
Arcutis Biotherapeutics, Inc. $22.0201/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252328460 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,813.11 101
PY2020 $1,037.63 58
PY2021 $1,421.23 76
PY2022 $2,163.64 94
PY2023 $11,540.94 100
PY2024 $31,128.94 155
PY2025 $28,288.05 160

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $786,454.78 322
PY2024 Principal investigator $495,841.34 528
PY2023 Recipient $15,198.50 3
PY2023 Principal investigator $623,456.67 650
PY2022 Principal investigator $195,872.13 77
PY2021 Principal investigator $192,250.45 64
PY2020 Principal investigator $312,094.81 64
PY2019 Principal investigator $232,294.91 35

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

322 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $3,537.36 12/31/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH LLC
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects with Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy No dispute reported 06/30/2026 1202532400
Principal investigator 1 ABBVIE INC. $1,529.40 12/31/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH LLC
A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata No dispute reported 06/30/2026 1202533157
Principal investigator 1 ABBVIE INC. $921.22 12/30/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202532244
Principal investigator 1 ABBVIE INC. $3,500.00 12/30/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202532246
Principal investigator 1 ABBVIE INC. $629.51 12/30/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202532258
Principal investigator 1 Incyte Corporation $90.00 12/19/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581459
Principal investigator 1 Incyte Corporation $3,613.50 12/19/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581469
Principal investigator 1 Incyte Corporation $1,634.00 12/19/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581473
Principal investigator 1 Incyte Corporation $126.00 12/19/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581477
Principal investigator 1 ABBVIE INC. $824.00 12/16/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202530678
Principal investigator 1 ABBVIE INC. $5,158.00 12/11/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202529980
Principal investigator 1 ABBVIE INC. $1,200.00 12/11/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202530278
Principal investigator 1 ABBVIE INC. $664.00 12/11/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202530302
Principal investigator 1 Incyte Corporation $780.00 12/11/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240588431
Principal investigator 1 Incyte Corporation $431.00 12/11/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240588439
Principal investigator 1 Incyte Corporation $104.00 12/11/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240588442
Principal investigator 1 Incyte Corporation $252.00 12/11/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240588445
Principal investigator 1 Incyte Corporation $763.00 12/11/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240588457
Principal investigator 1 ABBVIE INC. $2,264.70 12/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202528948
Principal investigator 1 ABBVIE INC. $8,167.53 12/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202529156
Principal investigator 1 ABBVIE INC. $5,750.00 12/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202529158
Principal investigator 1 Incyte Corporation $7,150.50 12/04/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581463
Principal investigator 1 Incyte Corporation $1,390.00 12/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240588435
Principal investigator 1 Incyte Corporation $2,326.10 12/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240588453
Principal investigator 1 Incyte Corporation $10,228.80 12/03/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581466
Principal investigator 1 ABBVIE INC. $4,872.00 12/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202526226
Principal investigator 1 Incyte Corporation $2.37 12/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588460
Principal investigator 1 Incyte Corporation $2.37 12/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588465
Principal investigator 1 Incyte Corporation $9.48 12/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588471
Principal investigator 1 Incyte Corporation $7.11 12/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588475
Principal investigator 1 Incyte Corporation $7.11 12/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588480
Principal investigator 1 Incyte Corporation $26.07 12/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588484
Principal investigator 1 Incyte Corporation $47.40 12/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588488
Principal investigator 1 Incyte Corporation $14.22 12/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588492
Principal investigator 1 Incyte Corporation $1.02 12/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588497
Principal investigator 1 Incyte Corporation $4.74 12/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588501
Principal investigator 1 ABBVIE INC. $796.83 11/26/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202525684
Principal investigator 1 ABBVIE INC. $702.66 11/26/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202525686
Principal investigator 1 Incyte Corporation $6,133.50 11/25/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581455
Principal investigator 1 Incyte Corporation $4,000.00 11/20/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581440
Principal investigator 1 Incyte Corporation $2,206.80 11/20/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581443
Principal investigator 1 Incyte Corporation $460.65 11/20/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581447
Principal investigator 1 Incyte Corporation $1,566.00 11/20/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240588427
Principal investigator 1 ABBVIE INC. $824.00 11/14/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202524381
Principal investigator 1 Incyte Corporation $539.25 11/14/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581437
Principal investigator 1 Incyte Corporation $1,566.00 11/13/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240588423
Principal investigator 1 Incyte Corporation $1,869.30 11/07/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581451
Principal investigator 1 ABBVIE INC. $6,500.91 11/05/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202522841
Principal investigator 1 ABBVIE INC. $3,652.90 11/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202521051
Principal investigator 1 ABBVIE INC. $7,608.00 11/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202521053
Principal investigator 1 ABBVIE INC. $1,605.90 11/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202521105
Principal investigator 1 ABBVIE INC. $600.00 10/30/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202519841
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $18,061.29 10/30/2025 Non-covered Recipient Entity
Skin Care Research, Llc
A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) No dispute reported 06/30/2026 1235993671
Principal investigator 1 Incyte Corporation $593.10 10/29/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581417
Principal investigator 1 Incyte Corporation $1,883.70 10/23/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581420
Principal investigator 1 ABBVIE INC. $5,000.00 10/17/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202517427
Principal investigator 1 ABBVIE INC. $152.56 10/16/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202517321
Principal investigator 1 Incyte Corporation $3,391.20 10/16/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581423
Principal investigator 1 ABBVIE INC. $20,678.76 10/09/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202515093
Principal investigator 1 ABBVIE INC. $3,204.48 10/09/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202516029
Principal investigator 1 ABBVIE INC. $9,927.00 10/09/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202516093
Principal investigator 1 Incyte Corporation $328.00 10/09/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240588408
Principal investigator 1 Incyte Corporation $104.00 10/09/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240588412
Principal investigator 1 Incyte Corporation $452.00 10/09/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240588418
Principal investigator 1 Novartis Pharmaceuticals Corporation $396.08 10/08/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190310266
Principal investigator 1 Incyte Corporation $1,869.30 10/03/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581413
Principal investigator 1 Incyte Corporation $180.00 10/03/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581428
Principal investigator 1 Incyte Corporation $260.00 10/03/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581433
Principal investigator 1 Incyte Corporation $3,132.00 10/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240588415
Principal investigator 1 ABBVIE INC. $1,992.00 09/30/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202512852
Principal investigator 1 Incyte Corporation $1,883.70 09/23/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581399
Principal investigator 1 Incyte Corporation $1,584.00 09/23/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240588334
Principal investigator 1 Incyte Corporation $1,883.70 09/18/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581409
Principal investigator 1 ABBVIE INC. $2,843.75 09/17/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202511220
Principal investigator 1 Incyte Corporation $5,530.50 09/12/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581405
Principal investigator 1 ABBVIE INC. $1,164.80 09/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202509388
Principal investigator 1 ABBVIE INC. $24,180.23 09/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202509646
Principal investigator 1 ABBVIE INC. $5,248.68 09/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202508050
Principal investigator 1 ABBVIE INC. $32.50 09/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202506977
Principal investigator 1 ABBVIE INC. $338.10 09/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202506979
Principal investigator 1 ABBVIE INC. $249.48 08/28/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202506267
Principal investigator 1 Incyte Corporation $2,447.10 08/26/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581391
Principal investigator 1 Incyte Corporation $452.00 08/26/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240588318
Principal investigator 1 Incyte Corporation $104.00 08/26/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240588321
Principal investigator 1 Incyte Corporation $63.00 08/26/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240588330
Principal investigator 1 Incyte Corporation $270.00 08/21/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581387
Principal investigator 1 Incyte Corporation $16,325.10 08/21/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581395
Principal investigator 1 ABBVIE INC. $793.32 08/14/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202504573
Principal investigator 1 ABBVIE INC. $100.00 08/14/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202504855
Principal investigator 1 ABBVIE INC. $78.81 08/12/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202504279
Principal investigator 1 ABBVIE INC. $74.20 08/07/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202503717
Principal investigator 1 ABBVIE INC. $48.60 08/07/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202503719
Principal investigator 1 ABBVIE INC. $13.91 08/07/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202503957
Principal investigator 1 Incyte Corporation $297.64 08/07/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240588325
Principal investigator 1 ABBVIE INC. $1,111.35 08/06/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202502350
Principal investigator 1 ABBVIE INC. $567.75 08/06/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202503575
Principal investigator 1 ABBVIE INC. $1,648.44 08/05/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202501170
Principal investigator 1 ABBVIE INC. $124.92 08/05/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202501258
Principal investigator 1 ABBVIE INC. $11,578.00 08/05/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202501260
Principal investigator 1 ABBVIE INC. $59.88 08/05/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202502196
Principal investigator 1 ABBVIE INC. $137.23 08/05/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202502208
Principal investigator 1 ABBVIE INC. $385.10 08/05/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202502212
Principal investigator 1 ABBVIE INC. $97.50 08/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202500992
Principal investigator 1 Incyte Corporation $24.68 08/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588337
Principal investigator 1 Incyte Corporation $16.18 08/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588341
Principal investigator 1 Incyte Corporation $0.31 08/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588345
Principal investigator 1 Incyte Corporation $8.22 08/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588348
Principal investigator 1 Incyte Corporation $4.86 08/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588352
Principal investigator 1 Incyte Corporation $11.45 08/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588354
Principal investigator 1 Incyte Corporation $16.18 08/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588358
Principal investigator 1 Incyte Corporation $11.45 08/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588363
Principal investigator 1 Incyte Corporation $62.27 08/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588367
Principal investigator 1 Incyte Corporation $2.12 08/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588373
Principal investigator 1 Incyte Corporation $24.68 08/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588377
Principal investigator 1 Incyte Corporation $8.22 08/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588382
Principal investigator 1 Incyte Corporation $8.22 08/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588385
Principal investigator 1 Incyte Corporation $8.22 08/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588389
Principal investigator 1 Incyte Corporation $8.22 08/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588393
Principal investigator 1 Incyte Corporation $8.22 08/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588397
Principal investigator 1 Incyte Corporation $8.22 08/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588401
Principal investigator 1 Incyte Corporation $8.22 08/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588404
Principal investigator 1 ABBVIE INC. $1,684.45 07/30/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202500430
Principal investigator 1 Incyte Corporation $12,615.30 07/30/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581359
Principal investigator 1 Incyte Corporation $15,319.80 07/30/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581370
Principal investigator 1 Incyte Corporation $810.00 07/22/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581354
Principal investigator 1 Incyte Corporation $1,853.10 07/22/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581379
Principal investigator 1 Incyte Corporation $305.63 07/22/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240590316
Principal investigator 1 Incyte Corporation $470.70 07/17/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581351
Principal investigator 1 Incyte Corporation $935.00 07/17/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240588302
Principal investigator 1 Incyte Corporation $447.00 07/17/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240588305
Principal investigator 1 Incyte Corporation $194.60 07/17/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240588309
Principal investigator 1 Incyte Corporation $1,774.60 07/17/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240588314
Principal investigator 1 ABBVIE INC. $440.00 07/10/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202497766
Principal investigator 1 Incyte Corporation $76.00 07/10/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581363
Principal investigator 1 Incyte Corporation $104.00 07/10/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581367
Principal investigator 1 Incyte Corporation $550.00 07/10/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581375
Principal investigator 1 Incyte Corporation $11,502.90 07/10/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240588298
Principal investigator 1 ABBVIE INC. $558.90 07/08/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202497016
Principal investigator 1 Eli Lilly and Company $100.00 07/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH LLC
A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK) OF BARICITINIB IN CHILDREN FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH ALOPECIA AREATA No dispute reported 06/30/2026 1187889376
Principal investigator 1 Incyte Corporation $1,853.10 07/04/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581383
Principal investigator 1 Incyte Corporation $4,000.00 07/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240590313
Principal investigator 1 Incyte Corporation $188.76 07/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240590320
Principal investigator 1 ABBVIE INC. $7,367.00 07/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202493995
Principal investigator 1 ABBVIE INC. $2,556.60 07/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202493997
Principal investigator 1 ABBVIE INC. $1,926.90 07/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202494099
Principal investigator 1 ABBVIE INC. $6,244.65 07/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202494101
Principal investigator 1 ABBVIE INC. $3,041.04 07/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202494103
Principal investigator 1 ABBVIE INC. $350.00 07/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202493713
Principal investigator 1 ABBVIE INC. $664.00 07/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202493723
Principal investigator 1 Incyte Corporation $6,627.60 06/24/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581345
Principal investigator 1 Novartis Pharmaceuticals Corporation $78,122.65 06/15/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190310268
Principal investigator 1 ABBVIE INC. $824.00 06/12/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202491087
Principal investigator 1 ABBVIE INC. $1,765.92 06/11/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202490847
Principal investigator 1 ABBVIE INC. $656.88 06/10/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202490689
Principal investigator 1 Incyte Corporation $2,191.50 06/05/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581343
Principal investigator 1 Incyte Corporation $1,259.00 06/05/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240588173
Principal investigator 1 Incyte Corporation $10,000.00 06/05/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240588178
Principal investigator 1 Incyte Corporation $2,000.00 06/05/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240588183
Principal investigator 1 Incyte Corporation $2,000.00 06/05/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240588186
Principal investigator 1 Incyte Corporation $2,500.00 06/05/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240588189
Principal investigator 1 Incyte Corporation $1,866.00 06/05/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240588193
Principal investigator 1 Incyte Corporation $1,400.00 06/05/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240588196
Principal investigator 1 ABBVIE INC. $5,575.65 06/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202487715
Principal investigator 1 ABBVIE INC. $6,417.00 06/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202487717
Principal investigator 1 ABBVIE INC. $100.32 06/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202487719
Principal investigator 1 ABBVIE INC. $2,193.82 06/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202487721
Principal investigator 1 Incyte Corporation $24.68 06/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588230
Principal investigator 1 Incyte Corporation $8.22 06/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588261
Principal investigator 1 Incyte Corporation $124.54 06/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588264
Principal investigator 1 Incyte Corporation $16.18 06/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588268
Principal investigator 1 Incyte Corporation $8.24 06/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588271
Principal investigator 1 Incyte Corporation $2.12 06/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588274
Principal investigator 1 Incyte Corporation $8.22 06/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588282
Principal investigator 1 Incyte Corporation $8.22 06/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588285
Principal investigator 1 Incyte Corporation $8.22 06/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588289
Principal investigator 1 Janssen Research & Development, LLC $100.00 06/03/2025 Non-covered Recipient Entity
Skin Care Research, Llc
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175187167
Principal investigator 1 ABBVIE INC. $1,575.45 05/29/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202486851
Principal investigator 1 ABBVIE INC. $112.04 05/29/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202486853
Principal investigator 1 ABBVIE INC. $664.00 05/29/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202487069
Principal investigator 1 ABBVIE INC. $996.00 05/29/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202487071
Principal investigator 1 Incyte Corporation $5,684.40 05/28/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581332
Principal investigator 1 Incyte Corporation $198.35 05/28/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240590299
Principal investigator 1 Incyte Corporation $400.00 05/28/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240590302
Principal investigator 1 ABBVIE INC. $7,000.00 05/27/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202486269
Principal investigator 1 ABBVIE INC. $824.00 05/27/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202486279
Principal investigator 1 Incyte Corporation $313.00 05/22/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581328
Principal investigator 1 Incyte Corporation $800.00 05/22/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581338
Principal investigator 1 Incyte Corporation $1,112.17 05/22/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240590305
Principal investigator 1 Incyte Corporation $4,000.00 05/22/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240590308
Principal investigator 1 Janssen Research & Development, LLC $900.00 05/22/2025 Non-covered Recipient Entity
Skin Care Research, Llc
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175187043
Principal investigator 1 Janssen Research & Development, LLC $450.00 05/22/2025 Non-covered Recipient Entity
Skin Care Research, Llc
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175187173
Principal investigator 1 ABBVIE INC. $1,818.38 05/15/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202485161
Principal investigator 1 Incyte Corporation $407.40 05/15/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581323
Principal investigator 1 ABBVIE INC. $884.00 05/13/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202484757
Principal investigator 1 Incyte Corporation $5,877.00 05/08/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581336
Principal investigator 1 ABBVIE INC. $1,375.20 05/07/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202483749
Principal investigator 1 ABBVIE INC. $13,627.89 05/07/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202483883
Principal investigator 1 ABBVIE INC. $94.58 05/06/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202481395
Principal investigator 1 ABBVIE INC. $1,515.30 05/06/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202482047
Principal investigator 1 ABBVIE INC. $36.17 05/06/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202482137
Principal investigator 1 ABBVIE INC. $36.17 05/06/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202482215
Principal investigator 1 ABBVIE INC. $7,167.00 05/06/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202482217
Principal investigator 1 ABBVIE INC. $172.50 05/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202480843
Principal investigator 1 Incyte Corporation $45.00 05/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240590295
Principal investigator 1 ABBVIE INC. $2,890.00 04/30/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202480523
Principal investigator 1 ABBVIE INC. $664.00 04/30/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202480527
Principal investigator 1 ABBVIE INC. $330.00 04/30/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202480547
Principal investigator 1 ABBVIE INC. $824.00 04/29/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202479827
Principal investigator 1 Incyte Corporation $1,965.60 04/28/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581307
Principal investigator 1 Janssen Research & Development, LLC $3,021.00 04/28/2025 Non-covered Recipient Entity
Skin Care Research, Llc
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175187092
Principal investigator 1 Janssen Research & Development, LLC $419.00 04/28/2025 Non-covered Recipient Entity
Skin Care Research, Llc
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175187100
Principal investigator 1 ABBVIE INC. $56.85 04/24/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202478980
Principal investigator 1 Incyte Corporation $3,944.39 04/24/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1240588212
Principal investigator 1 Incyte Corporation $3,360.60 04/23/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581314
Principal investigator 1 ABBVIE INC. $664.00 04/17/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202477388
Principal investigator 1 ABBVIE INC. $336.70 04/16/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202476922
Principal investigator 1 ABBVIE INC. $54.84 04/15/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202476468
Principal investigator 1 Incyte Corporation $58.00 04/15/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581303
Principal investigator 1 ABBVIE INC. $222.56 04/10/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202475731
Principal investigator 1 ABBVIE INC. $1,504.00 04/09/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202475109
Principal investigator 1 ABBVIE INC. $327.16 04/09/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202475125
Principal investigator 1 ABBVIE INC. $3,459.00 04/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202470364
Principal investigator 1 ABBVIE INC. $14,679.00 04/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202470731
Principal investigator 1 ABBVIE INC. $1,415.55 04/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202470734
Principal investigator 1 ABBVIE INC. $5,275.67 04/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202470737
Principal investigator 1 ABBVIE INC. $595.80 04/03/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202470881
Principal investigator 1 Incyte Corporation $2,500.00 04/03/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581311
Principal investigator 1 Incyte Corporation $270.00 04/03/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581318
Principal investigator 1 ABBVIE INC. $219.12 04/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202468427
Principal investigator 1 Incyte Corporation $190.80 04/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588220
Principal investigator 1 Incyte Corporation $31.80 04/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588224
Principal investigator 1 Incyte Corporation $217.30 04/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588226
Principal investigator 1 Incyte Corporation $16.14 04/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588235
Principal investigator 1 Incyte Corporation $10.76 04/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588238
Principal investigator 1 Incyte Corporation $32.28 04/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588243
Principal investigator 1 Incyte Corporation $21.20 04/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588246
Principal investigator 1 Incyte Corporation $47.70 04/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588250
Principal investigator 1 Incyte Corporation $63.60 04/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588254
Principal investigator 1 Incyte Corporation $100.70 04/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588258
Principal investigator 1 Incyte Corporation $43.04 04/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588279
Principal investigator 1 Incyte Corporation $16.14 04/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588293
Principal investigator 1 Incyte Corporation $12,000.00 04/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240590273
Principal investigator 1 Incyte Corporation $1,500.00 04/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240590277
Principal investigator 1 Incyte Corporation $1,000.00 04/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240590282
Principal investigator 1 Incyte Corporation $600.00 04/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240590286
Principal investigator 1 Incyte Corporation $1,000.00 04/01/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240590291
Principal investigator 1 Incyte Corporation $2,500.00 03/27/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1240588208
Principal investigator 1 ABBVIE INC. $25,264.00 03/26/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202466250
Principal investigator 1 Incyte Corporation $1,853.10 03/25/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581296
Principal investigator 1 Janssen Research & Development, LLC $58.00 03/21/2025 Non-covered Recipient Entity
Skin Care Research, Llc
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175187243
Principal investigator 1 ABBVIE INC. $824.00 03/20/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202465013
Principal investigator 1 ABBVIE INC. $511.89 03/20/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202465017
Principal investigator 1 ABBVIE INC. $2,547.60 03/19/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202464346
Principal investigator 1 Eli Lilly and Company $2,490.00 03/19/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
PSOSA (PSORIASIS SPECIAL AREAS) - A US-BASED, SINGLE-ARM, PROSPECTIVE, MULTICENTER, OBSERVATIONAL STUDY OF NAIL AND SCALP PSORIASIS IMPROVEMENT IN PATIENTS TREATED WITH IXEKIZUMAB No dispute reported 06/30/2026 1187889414
Principal investigator 1 Incyte Corporation $104.00 03/14/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581299
Principal investigator 1 ABBVIE INC. $37.09 03/11/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202462313
Principal investigator 1 ABBVIE INC. $664.00 03/11/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202462317
Principal investigator 1 ABBVIE INC. $664.00 03/11/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202462399
Principal investigator 1 ABBVIE INC. $5,536.68 03/07/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202459882
Principal investigator 1 ABBVIE INC. $7,237.65 03/07/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202459885
Principal investigator 1 ABBVIE INC. $5,275.67 03/07/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202460006
Principal investigator 1 ABBVIE INC. $3,750.00 03/06/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202456991
Principal investigator 1 Incyte Corporation $1,245.50 03/05/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1240588216
Principal investigator 1 Incyte Corporation $1,853.10 03/04/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581291
Principal investigator 1 ABBVIE INC. $5,802.00 02/27/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202454272
Principal investigator 1 ABBVIE INC. $92.74 02/27/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202454277
Principal investigator 1 ABBVIE INC. $166.92 02/27/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202454281
Principal investigator 1 ABBVIE INC. $182.40 02/26/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202453918
Principal investigator 1 ABBVIE INC. $124.90 02/20/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202452782
Principal investigator 1 ABBVIE INC. $1,648.00 02/20/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202452789
Principal investigator 1 ABBVIE INC. $832.71 02/20/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202452793
Principal investigator 1 ABBVIE INC. $3,300.00 02/20/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202452797
Principal investigator 1 ABBVIE INC. $996.00 02/20/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202452835
Principal investigator 1 Eli Lilly and Company $2,500.00 02/20/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH LLC
AN OPEN-LABEL, 24-WEEK STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS AND SKIN OF COLOR No dispute reported 06/30/2026 1187890514
Principal investigator 1 Incyte Corporation $2,800.00 02/20/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581511
Principal investigator 1 Incyte Corporation $1,000.00 02/20/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581514
Principal investigator 1 Incyte Corporation $4,600.00 02/20/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581519
Principal investigator 1 ABBVIE INC. $504.85 02/19/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202452464
Principal investigator 1 ABBVIE INC. $1,540.00 02/18/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202452169
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $10,872.81 02/14/2025 Non-covered Recipient Entity
Skin Care Research, Llc
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE) No dispute reported 06/30/2026 1235993673
Principal investigator 1 Janssen Research & Development, LLC $58.00 02/14/2025 Non-covered Recipient Entity
Skin Care Research, Llc
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175187297
Principal investigator 1 ABBVIE INC. $2,119.30 02/06/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202447119
Principal investigator 1 ABBVIE INC. $3,209.10 02/06/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202447123
Principal investigator 1 ABBVIE INC. $824.00 02/06/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202447641
Principal investigator 1 ABBVIE INC. $6,814.44 02/06/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202447645
Principal investigator 1 ABBVIE INC. $5,318.00 02/05/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202444098
Principal investigator 1 ABBVIE INC. $128.04 01/30/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202443068
Principal investigator 1 Amgen Inc. $1,210.00 01/30/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INCORPORATED
A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) No dispute reported 06/30/2026 1246648216
Principal investigator 1 ABBVIE INC. $1,017.72 01/29/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202441767
Principal investigator 1 Incyte Corporation $2,191.50 01/29/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581497
Principal investigator 1 ABBVIE INC. $1,114.00 01/28/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M23-696 - A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up) No dispute reported 06/30/2026 1202441519
Principal investigator 1 Incyte Corporation $58.00 01/23/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1240588205
Principal investigator 1 Amgen Inc. $24,219.11 01/21/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INCORPORATED
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246648221
Principal investigator 1 Incyte Corporation $6,347.70 01/17/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581503
Principal investigator 1 ABBVIE INC. $2,800.00 01/16/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202439203
Principal investigator 1 Janssen Research & Development, LLC $3,256.00 01/16/2025 Non-covered Recipient Entity
Skin Care Research, Llc
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175187273
Principal investigator 1 ABBVIE INC. $7,092.00 01/14/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M23-696 - A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up) No dispute reported 06/30/2026 1202438245
Principal investigator 1 ABBVIE INC. $666.48 01/10/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202437929
Principal investigator 1 Incyte Corporation $52.00 01/09/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581480
Principal investigator 1 Incyte Corporation $52.00 01/09/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581483
Principal investigator 1 Incyte Corporation $723.75 01/09/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581487
Principal investigator 1 Incyte Corporation $2,500.00 01/09/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581491
Principal investigator 1 Incyte Corporation $83.40 01/09/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581494
Principal investigator 1 Incyte Corporation $12,000.00 01/09/2025 Non-covered Recipient Entity
RENDON CENTER THE DERMATOLOGY AND AESTHETIC CENTER
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240581508
Principal investigator 1 Incyte Corporation $1,229.58 01/04/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1240588201
Principal investigator 1 ABBVIE INC. $664.00 01/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202433597
Principal investigator 1 ABBVIE INC. $2,119.30 01/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202433601
Principal investigator 1 ABBVIE INC. $3,592.90 01/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202433673
Principal investigator 1 ABBVIE INC. $996.00 01/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202433677
Principal investigator 1 ABBVIE INC. $1,376.00 01/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202433995
Principal investigator 1 ABBVIE INC. $2,694.00 01/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH INC
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202433999
Principal investigator 1 Incyte Corporation $6.36 01/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588135
Principal investigator 1 Incyte Corporation $137.40 01/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588137
Principal investigator 1 Incyte Corporation $49.44 01/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588141
Principal investigator 1 Incyte Corporation $74.04 01/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588144
Principal investigator 1 Incyte Corporation $62.27 01/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588148
Principal investigator 1 Incyte Corporation $54.76 01/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588151
Principal investigator 1 Incyte Corporation $64.72 01/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588155
Principal investigator 1 Incyte Corporation $24.66 01/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588159
Principal investigator 1 Incyte Corporation $24.66 01/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588162
Principal investigator 1 Incyte Corporation $24.66 01/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588166
Principal investigator 1 Incyte Corporation $24.66 01/02/2025 Non-covered Recipient Entity
SKIN CARE RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240588169